What is your approach to first line systemic therapy in metastatic PD-L1 positive cervical cancer?
Do you include pembrolizumab with platinum-taxane + bevacizumab or reserve it as a second line option?
Community PollStarted
What is your approach to first line systemic therapy in metastatic PD-L1 positive cervical cancer?
62 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Gynecologic Oncology · Center of Hope
Answered on
Without question, pembrolizumab should be included in first line systemic therapy and not reserved as a second line option. The transformative results from KEYNOTE-826 led to FDA approval on 10/13/21 of pembrolizumab in combination with platinum and taxane therapy (+ bevacizumab) for first line trea...
Join for free or sign in to see the full answer
Mednet Member
Gynecologic Oncology · ProMedica Toledo Hospital
Answered on
Also, radiation for primary site depending on symptoms. In addition, look for other disease sites that may require individual attention.
Join for free or sign in to see the full answer